Kornimate/medical-research-clean huggingface dataset:
dynamic changes of gut microbiota in uc after fmt

Conditions: Ulcerative Colitis

Summary: a prospective study to investigate the dynamic changes of gut microbiota through colonic transendoscopic enteral tubing in patients with ulcerative colitis after fecal microbiota transplantation.

colonic transendoscopic enteral tubing (tet) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (fmt) and the whole-colon enema treatment. this tube also can serve as a medium for collecting gut microbiota. fecal microbiota transplantation (fmt) was identified to be promising for ulcerative colitis (uc). this study aims to investigate the dynamic changes of gut microbiota in patients with uc after fmt.

Eligibility criteria:
inclusion criteria: * patients were diagnosed with mild or moderate ulcerative colitis. * patients need colonic tet and fmt * must be able to colonic tet and no contraindication by endoscopic examination, consent colon tet implantation and not associated with severe intestinal lesions such as fistula, stenosis, complex perianal lesions, severe ileocecal or ascending colon lesions resulting in no proper site for titanium clip fixation. * age \> 7 years old and \< 65 years old exclusion criteria: * gut microbiota was not collected successfully

Keywords: transendoscopic enteral tubing gut microbiota ulcerative colitis
12 week open, non-comparative switch study of oral ziprazidone in previously treated schizophrenic patients

Conditions: Schizophrenia

Summary: there has been evidence that ziprasidone is efficacious in decreasing the magnitude of both positive and negative symptoms of schizophrenia, and also effective in the treatment of depressive symptoms. it shows good tolerance with low incidence of extrapyramidal side effects and does not significantly influence body weight. as it has been shown that ziprasidone is efficacious and safe in patients who have been pretreated with other antipsychotic that has to be withdrawn either due to the side effects or not satisfied efficacy. the purpose of the study was to provide further evidence for the efficacy and safety of patients with schizophrenia and allow for psychiatrists in hungary to gain experience with the drug before wide commercial availability.

study was terminated due to difficulty in enrolling the targeted number of patients on march 1, 2005, last subject last visit date was feb.16, 2005. there were no safety concerns involved in the decision to terminate the trial.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of schizophrenia according to dsm-iv-iv from patient's medical files * subjects with current treatment with typical or atypical neuroleptics which should be changed exclusion criteria: * patients with significant cardiovascular illness (recent acute myocardial infarction, uncompensated heart failure, cardiac arrhythmia) * in the patients' history clinically significant ecg abnormalities particularly prolongation of qt interval of more than 500 ms
safety and tolerability of preservative-free polyhexamethylene biguanide (phmb) ophthalmic solution in healthy subjects

Conditions: Acanthamoeba Keratitis

Summary: randomized, double-masked, placebo-controlled, multiple center, parallel-group phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free phmb ophthalmic solution compared to placebo in healthy subjects

the primary objective of the study is to establish the ocular safety and tolerability, and systemic safety of 3 different concentrations of preservative-free phmb in healthy subjects. safety and tolerability will be compared to those of a placebo.the phmb bioavailability in plasma will also be assessed

Eligibility criteria:
inclusion criteria: * able and willing to give informed consent. * man or woman of any race and 18 to 55 years of age, inclusive. * body mass index of 20-30 kg/m2 * willing and able to attend required study visits. * bilateral visual acuity \>6/10. * intraocular pressure (iop) of 14-21 mmhg. * ophthalmologic examination without abnormalities. * medical history without major pathology. * laboratory test results without deviations from the normal range. * female subjects of childbearing potential with negative urine pregnancy test and using effective contraception during the study. exclusion criteria: * presence of bacterial ocular infections. * presence of any concomitant ocular pathology. * performing activities likely to result in an irritated conjunctiva during the study (including heavy alcohol intake, swimming in chlorinated water and heavy smoking). * contact lenses wearing . * ocular surface fluorescein staining score \>3. * use of topical or systemic antibiotics, antihistamines, decongestants and non-steroidal anti-inflammatory agents as well as steroids within 7 days before screening. * known or suspected allergy to biguanides or intolerance to any other ingredient of the test treatments. * ocular surgery performed within 12 months before screening. * participation in another clinical study in the preceding 30 days. * one functional eye. * pregnancy or breastfeeding. * use of recreational drugs.
safety study of the vascular wrap paclitaxel-eluting mesh for hemodialysis vascular access

Conditions: End Stage Renal Failure on Dialysis; Hyperplasia

Summary: the purpose of this study is to determine whether the long term use of the experimental vascular wrap(tm) paclitaxel-eluting mesh is safe in the treatment of subjects needing hemodialysis access (via an expanded polytetrafluoroethylene (eptfe) graft).

the primary objective of this study is to determine long term safety of the lifespan® eptfe vascular graft and vascular wrap(tm) paclitaxel-eluting mesh in comparison to the lifespan® graft alone.

Eligibility criteria:
inclusion criteria: to be considered for enrollment, subjects must: * have been randomized in protocol 012-vwav06; * have signed and dated an irb-approved written informed consent to participate in 012-vwav06 as well as this study; * be willing to comply with all aspects of the evaluation schedule over a period of 60 months post device insertion; * allow representatives of the sponsor, designated clinical research organization (cro), institutional review board (irb), the ethics committee, and u.s. food and drug administration (fda) to review his/her relevant medical records. exclusion criteria: * subjects who withdrew or were withdrawn from study 012-vwav06.

Keywords: dialysis hemodialysis neointimal hyperplasia
postoperative analgesis in total knee arthroplasty

Conditions: Knee Arthroplasty

Summary: postoperative analgesic treatment methods are applied to patients who have undergone knee arthroplasty. these applications are a routine part of the procedure. it is medically and ethically necessary. postoperative analgesia applications are started during the intraoperative period and continued during the postoperative period. the analgesia protocol to be used is shaped by the characteristics of the patient and the skill and experience of the anesthesiologist. the scientifically accepted method is multimodel analgesia protocols. these protocols cover a wide range from paracetamol to opioids to peripheral and central blocks (methods such as suprainguinal fascia iliac block (sfip), adductor block (acb) and infiltration analgesia (ipack) applied between the posterior elements of the knee and the popliteal artery). our aim in this study is to evaluate the effects of analgesia protocols applied to patients undergoing knee arthroplasty surgery on inflammatory biomarkers (such as neutrophil lymphocyte ratio (nlr), platelet lymphocyte ratio (plr), systemic immune inflammation score (sii), lactate) obtained from routine blood and blood gas examinations in the first 24 hours of the postoperative period.


Eligibility criteria:
inclusion criteria: * 18-75 years old * asa i,ii,iii patients * patients who will undergo elective surgery exclusion criteria: * patients undergoing emergency surgery * patients with bleeding diathesis * those who are allergic or sensitive to local anesthetics and opioid drugs, * those who use gabapentinoids * patients with neurocognitive disorders, * patients with chronic organ failure, * mothers with suspected pregnancy, pregnant or breastfeeding mothers * patients using opioids * those who use steroids * those with a history of substance use

Keywords: postoperative pain knee arthroplasty
phase 1, open-label, dose-escalation trial with cd38-sada:177 lu-dota drug complex in subjects with relapsed or refractory non-hodgkin lymphoma

Conditions: Non-hodgkin Lymphoma

Summary: patients with non-hodgkin lymphoma will be treated with cd38-sada:177lu-dota complex (the imp is a two-step radioimmunotherapy, delivered as two separate products cd38-sada and 177lu-dota) to establish optimal and safe therapeutic doses and dosing schedule of cd38-sada, and 177lu-dota.


Eligibility criteria:
inclusion criteria: * target population must have relapsed, progressive or refractory non-hodgkin lymphoma and be ineligible for or have exhausted standard therapeutic options that may prolong survival * the subject must have fluoro-deoxyglucose (fdg)-avid lymphoma with measurable disease * cd38 positive tumor at most recent biopsy (new or archival) documented at central laboratory * subject must have an eastern cooperative oncology group (ecog) performance status score of 0, 1, or 2 * each subject must sign an icf indicating that he or she understands the purpose of, and procedures required for the trial and is willing to participate in the trial. exclusion criteria: * primary central nervous system lymphoma or known central nervous system involvement with lymphoma * systemic chemotherapy, radiotherapy, immunotherapy, or major surgery administered within 3 weeks (for nitrosoureas within 6 weeks) prior to the first dose of cd38-sada * radioimmunotherapy within 100 days prior to the first dose of cd38-sada * autologous stem cell transplantation within 42 days prior to the first dose of cd38-sada * treatment with approved car-t within 100 days prior to the first dose of cd38-sada * \>40% lymphoma bone marrow involvement
scapula retraction exercises in subacromial pain syndrome

Conditions: Rotator Cuff Impingement Syndrome

Summary: scapula retraction exercises are often recommended as a part of the exercise programs. the primary aim of this study is to investigate the initial effect of the scapula retraction exercises on acromiohumeral distance (ahd) at varying shoulder abduction angles and to compare asymptomatic subjects. the secondary aim of this study is to investigate the effect of scapula retraction exercises on ahd values and symptoms (pain and disability) in patients with sps.

subacmial pain syndrome (sps) is a common cause of shoulder pain and dysfunction in the general population. exercise interventions is thought as a primary choice in clinical settings. scapula retraction exercises are commonly recommended as a part of the exercise programs. applying scapula retraction exercises at varying shoulder abduction angles could restore balance between the scapulothoracic muscles. since the scapulothoracic muscles dynamically control subacromial space, scapula retraction exercises could further help to maintain ahd during arm elevation. the primary aim of this study is to investigate the initial effect of the scapula retraction exercises on acromiohumeral distance (ahd) at varying shoulder abduction angles and to compare asymptomatic subjects. the secondary aim of this study is to investigate the effect of scapula retraction exercises on ahd values and symptoms (pain and disability) in patients with sps.

Eligibility criteria:
inclusion criteria: inclusion criteria: * aged between 18-45 * painful arc of movement during flexion or abduction; * positive neer or kennedy-hawkins impingement signs * pain on resisted lateral rotation, abduction or empty can test. exclusion criteria: * previous shoulder surgery; * shoulder pain reproduced by neck movement; * clinical signs of full-thickness rc tears; or * adhesive capsulitis.

Keywords: pain severity functional status acromiohumeral distance shoulder pain
effect of fermented products and probiotics on the condition of the implant

Conditions: Implant

Summary: 126 individuals with peri-implant disease and health, aged between 18-70 years, who applied to bolu university faculty of dentistry periodontology clinic, participated in the study.the inclusion criteria for patient participation in the study were: age of patients between 18 and 70 years; the presence of at least 20 natural teeth in the oral cavity; systemic health. peri-implant status was determined by the clinician (t.ş.) by evaluating dental implants' plaque, gingival index, bleeding on probing, pocket depth measurements, and clinical attachment level. in addition, them systemic illness, pregnancy, breastfeeding status, medication, antibiotic use, and whether they smoked were questioned. systemically unhealthy patients who did not use antibiotics within a month, were breastfeeding or pregnant, had uncontrolled diabetes, rheumatic fever, a history of lung and kidney disorders, and used drugs that could affect periodontal tissues were not included in the study. after examination, the patients were divided into three groups according to their disease: peri-implantitis (42 patients), peri-implantitis (42 patients), and peri-implant health (42 patients). demographic characteristics (age, weight, gender, height, education, and employment status) of the participants were collected with a questionnaire. with this survey, fermented foods and probiotic products such as bacon, soy sauce, pickles, sourdough bread, whole grain, rye, wholemeal bread, ayran, kefir, turnip, vinegar (homemade), pomegranate syrup (homemade), probiotic beverage, the frequency and amount of consumption of cheese, dark chocolate, tablets, capsules, chassis, butter and other (kimchi, sauerkrauth, miso soup, fermented herring, kombucha, etc.) were determined. it was requested to determine the relationship between the health and disease of the implant and the frequency of consumption of fermented and probiotic products and foods in individuals with implants.


Eligibility criteria:
inclusion criteria: * systemically healthy individuals * individuals between the ages of 18-70 exclusion criteria: * no use of antibiotics within one month * breastfeeding or being pregnant * uncontrolled diabetes, rheumatic fever, history of lung and kidney disorders, and drug use that will affect periodontal tissues

Keywords: fermented foods probiotics peri-implant health peri-implant mucositis peri-implantitis
carbetocin versus oxytocin for prophylaxis against atonic primary post-partum hemorrhage

Conditions: Atonic Postpartum Hemorrhage; High Risk Pregnancy

Summary: comparison between carbetocin and oxytocin as prophylaxis against primary postpartum hemorrhage.

patients will be allocated randomly by simple randomization into either 1- the control group which will be given 10 iu oxytocin intravenously, or 2- the treatment group which will be given 100 micrograms of carbetocin intravenously. the trial will be conducted on patients with high risk of developing atonic primary postpartum hemorrhage. the trial will be single blinded. all patients fulfilling the inclusion criteria undergoing elective caesarean section will be approached by the treating physician and will be asked to participate in the study. an informed written consent will be taken from each patient. the data collected will include base line characteristics such as age, parity, body mass index, the risk for postpartum hemorrhage in each patient, amount of blood loss, blood units given, complete blood picture (pre and post operative) and coagulation profile.

Eligibility criteria:
inclusion criteria: * • high risk patients for post-partum hemorrhage who will subjected to caeserean section either elective or in labour at or after 36 weeks of gestation. this should include one or more of the following: 1. history of postpartum hemorrhage. 2. delivery of a macrosomic baby (\> 4000 g). 3. multiple gestation. 4. polyhydramnios. 5. grand multiparity. 6. interstitial or submucous fibroid. (single larger than 4 cm or multiple myomata) 7. chorioamnionitis. exclusion criteria: * • patients without high risk for post-partum hemorrhage. * patients at high risk for postpartum hemorrhage but will deliver vaginally. * patients with medical disorders complicating pregnancy. * patients with coagulation defects. * preterm pregnancies.

Keywords: atonic postpartum hemorrhage carbetocin oxytocin high risk pregnancy
prospective longitudinal 1-year study of the correlation between cognitive functioning in patients with clinically isolated syndrome suggestive of multiple sclerosis and disconnection in the brain assessed by mri

Conditions: Clinically Isolated Demyelinating Syndromes; Multiple Sclerosis; Cognitive Deficiencies; Brain MRI

Summary: clinically isolated demyelinating syndromes (cis) can evolve into multiple sclerosis (ms). cognitive deficiencies could occur at this early stage and concern mainly information processing speed (ips) and their mechanisms are not fully understood. diffusion tensor imaging (dti) can help in the understanding of these mechanisms.

this is a prospective cohort, observational, longitudinal, monocentric study. this study will include 60 patients with cis followed for 1 year and 60 healthy subjects.

Eligibility criteria:
inclusion criteria: * patients: * men and women * ≥16 years * fluent french speaker * clinically isolated neurological syndrome (cis) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (ms) whatever the mode of presentation * between 60 and 180 days from the onset * at least two clinically silent lesions on their t2-weighted brain or spinal mri scan with a size of at least 3 mm, at least one of which being cerebral, ovoid, or periventricular * having a medical insurance * free and informed consent signed * controls: * men and women * ≥18 years * fluent french speaker * having a medical insurance * free and informed consent signed exclusion criteria: * patients: * prior documented neurological episode suggestive of ms. * other ongoing neurological diseases. * known chronic systemic diseases as judged by the investigator (for instance: lupus, gougerot-sjögren, sarcoidosis, sclerodermia, crohn disease,...). * other causes (trauma, tumor, radiotherapy, infections, vascular diseases, neuromyelitis optica). * current dependence on alcohol or drugs. * dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 15 days * mri contra-indications. * steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily. * controls: * known chronic psychiatric or neurologic diseases which could interfere with neuropsychological testing, not taking into account stable and mild depressive syndrome * known chronic systemic diseases as judged by the investigator (for instance: lupus, gougerot-sjögren, sarcoidosis, scleroderma, crohn disease...). * ms familial history * current dependence on alcohol or drugs * known cognitive impairment * prior neuropsychological testing with the same tests less than one year * dosage change, stop or start of hypnotic or anxiolytic or antidepressive treatment less than 2 months * steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily. * mri contra-indications * steroid treatment less than one month (be taken orally or by infusion) at the dosage of 500mg daily.
treatment of patients with advanced rectum cancer with capecitabine and oxaliplatin before, under and after radiation and with adding cetuximab to k-ras wild-type patients

Conditions: Rectum Cancer

Summary: response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

dynamic mri will be used to monitor the effect of the treatment and will be compared to pathologic results.

Eligibility criteria:
inclusion criteria: * advanced rectum cancer exclusion criteria: * prior radiation

Keywords: cetuximab rectum cancer radiation mri
trends of cancer incidence and mortality in russia

Conditions: Oncology; Cancer

Summary: the study aims to assess the dynamics of incidence and mortality for all major groups of cancers for which the national data is available for the longest possible time series. the data obtained from publicly available sources are used.


Eligibility criteria:
non applicable
multicentric trial of the treatment of huntington's disease by cysteamine (rp103)

Conditions: Huntington's Disease

Summary: the purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic huntington's disease by comparing two groups of patients (cysteamine vs placebo) on the results of the unified huntington's disease rating scale (uhdrs, huntington study group 1996).


Eligibility criteria:
inclusion criteria: * clinically disease-registered for at least one year, leading to consult (abnormal movements, neuropsychiatric disorders, neuropsychological impairment). * unified huntington's disease rating scale motor ≥ 5 * total functional capacity \> 10 (≥ 11) * huntington disease diagnosed with abnormal number of cag repeats: 38 \< nucleotide expansion (cag) * age between 18 and 65 * voluntarily patient consent * patients willing and able to take oral medications, and comply with the specific procedures of the study exclusion criteria: * severe cognitive impairment or neuropsychiatric troubles. * no drug compliance to previous treatment. * patients with contra indication to the realization of imaging studies (including claustrophobia ) . * patients who have not given their written and informed consent signed . * no national health insurance affiliation * private patients of their liberty by judicial or administrative decision, or patients under supervision. * pregnant women ( pregnancy test will be carried out systematically for women at risk) or lactating . * women who could become pregnant during the study period and with no contraception. * patients who have developed hypersensitivity to cysteamine or penicillamine ( against indication of cysteamine ) . * brain damage intercurrent mri. brain morphological abnormalities , other than those characteristic of the disease . * disease - associated with neurological repercussions. * affection - visceral serious , scalable , involving life-threatening. * mental - disorder may disrupt accession to the protocol , including a history of spontaneous and / or drug-induced hallucinations history of severe depression that required repeated hospitalizations , history of repeated suicide attempts . * participation in progress, or interrupted for less than three months, a therapeutic protocol of huntington's disease . * patients with a history of surgical interventions to improve the symptoms of huntington 's disease such as graft neuron, deep brain stimulation, infusion of neurotrophic agent